No quarterly revenue total was found in PASITHEA THERAPEUTICS CORP.'s SEC filings.
Pasithea Therapeutics Corp. (KTTA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-5.27M
-41.9% vs year-ago quarter
Operating cash flow
$-4.71M
-21.7% vs year-ago quarter
Free cash flow
—
EPS
$-0.16
+75.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
33.41M
+348.9% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KTTA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Miami Beach, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1841330
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$5.7M | -$4.9M | -$10.3M | -$3.1M | -$3.8M |
| Net income | -$5.3M | -$2.9M | -$10.1M | -$3.0M | -$3.7M |
| Diluted EPS | -$0.16 | -$0.12 | -$0.80 | -$0.41 | -$0.66 |
| Operating cash flow | -$4.7M | -$4.8M | -$5.4M | -$2.9M | -$3.9M |
| Total assets | $51.7M | $56.4M | $60.2M | $13.6M | $17.0M |
| Total liabilities | $1.9M | $1.5M | $5.0M | $1.4M | $1.8M |
| Stockholders' equity | $49.8M | $54.8M | $55.2M | $12.2M | $15.2M |
| Cash and investments | $45.7M | $50.4M | $55.2M | $4.1M | $7.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 16, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 21, 2026 | Aug 20, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| ARS | Annual report to shareholders | Aug 7, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
All 344 Pasithea Therapeutics Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.